1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Summit Therapeutics agreed on September 28, 2026 to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, and also signed a separate clinical trial collaboration with AstraZeneca on sonesitatug vedotin combined with ivonescimab. Shareholders would face dilution once the preferred converts into common stock, which is subject to conditions and a registration statement, and the company must redeem the preferred for cash if a required share authorization is not effective within 18 months.
Purchase price of $18,356.14 per preferred share, based on a common stock price of $18.3561; each preferred share converts into 1,000 common shares
Closing is expected within five business days of the Purchase Agreement, subject to customary conditions
Conversion is barred until the later of any Hart-Scott-Rodino waiting period expiration and effectiveness of the authorized share increase charter amendment
Company must file a resale registration statement within 60 days after closing; cash redemption required if the share increase is not effective within 18 months
Futurewave Acquisition Corp (FWAC), a Nasdaq-listed special purpose acquisition company, signed a merger agreement with Olympian Group Inc., a Cayman Islands holding company of Hong Kong-based HK Shang Ge Industrial Limited, which provides integrated chip and electronic component solutions. Olympian shareholders would receive 40,000,000 Purchaser ordinary shares valued at $10.00 per share, based on a Company Net Value of $400,000,000, and the combined company is expected to be Nasdaq-listed, subject to shareholder and regulatory approvals. The deal is not yet completed and the filing sets a closing deadline of June 26, 2027, unless extended.
Olympian shareholders to receive 40,000,000 Purchaser ordinary shares valued at $10.00 each, based on a $400,000,000 Company Net Value
Board of the combined company to have five directors, one appointed by Futurewave and four by Olympian
Either party may terminate if closing has not occurred by June 26, 2027, subject to extension and exceptions
Closing requires Futurewave and Olympian shareholder approvals, an effective Form F-4 registration statement, and HSR or other antitrust clearance
At its 2026 Annual Meeting on September 24, 2026, Korn Ferry stockholders elected all nine director nominees, approved an advisory resolution on executive pay, approved the amended and restated 2022 Stock Incentive Plan, and ratified Ernst & Young LLP as auditor for fiscal 2027. The amended plan adds 1,400,000 shares for stock-based awards and extends its term to September 24, 2036, which sets the terms under which future equity may be granted to employees and directors.
Plan adds 1,400,000 shares available for stock-based awards and extends term to September 24, 2036
Plan approved with 43,102,365 votes for and 2,155,490 against
Executive compensation advisory resolution approved with 43,800,129 votes for and 1,145,915 against
Ernst & Young LLP ratified as independent auditor for fiscal 2027 with 46,296,359 votes for
On September 28, 2026, AAR agreed to acquire a 65% controlling interest in MRO Holdings, an aircraft maintenance provider, for an estimated cash price of $1,819,174,310 plus Series A preferred stock with an agreed value of $780,825,690, subject to adjustments and closing conditions including regulatory approvals. The deal is expected to close in AAR's fiscal third quarter ending February 2027 and is to be funded partly by about $2.1 billion of new debt, which AAR expects to take net leverage to about 3.6x at closing. The filing also notes that a private investment in public equity offering may dilute existing stockholders, and the company's fiscal 2026 adjusted EBITDA was $401.1 million, up from $324.2 million.
Estimated cash purchase price of $1,819,174,310 and Series A preferred stock with an agreed value of $780,825,690, plus a $22,500,000 escrow deposit
Implied enterprise value of $4.0 billion; AAR expects about $2.1 billion of new debt financing and net leverage of about 3.6x at closing
Expected close in fiscal third quarter ending February 2027, subject to regulatory approvals; termination fee of $100,000,000 ($150,000,000 if the outside date is extended) applies if competition approvals fail
Press release shows fiscal 2026 net income of $187.7 million versus $12.5 million in fiscal 2025, and adjusted EBITDA of $401.1 million versus $324.2 million
NETSOL reported record full-year fiscal 2026 revenue of $74.4 million, up 12.5% and above its $73 million guidance, and operating income nearly doubled to $6.9 million. GAAP net income attributable to NETSOL was $2.95 million, or $0.25 per diluted share, roughly flat with the prior year's $0.25, as a foreign exchange swing and higher non-controlling interest offset operating gains. The company also issued fiscal 2027 guidance calling for revenue growth of 13% to 16%.
Fourth-quarter fiscal 2026 revenue rose 12.5% to a record $20.7 million, and operating income rose 40.2% to $4.5 million.
Full-year GAAP net income attributable to NETSOL was $2.95 million, or $0.25 per diluted share, compared with $2.9 million, or $0.25, a year earlier.
Fiscal 2027 guidance: revenue growth of 13% to 16%, gross margin of approximately 50% or better, and adjusted EBITDA growth of 15% to 25%.
Cash was $27.1 million at June 30, 2026, and operating cash flow was $13.9 million versus $0.4 million a year earlier.
On September 23, 2026, independent director George Kollitides notified the board of D. Boral Acquisition I Corp. of his resignation, effective immediately, citing personal reasons. The company said the resignation was not related to any disagreement on its operations, policies or practices.
Director George Kollitides resigned from the board, effective immediately.
Notice of resignation given to the board on September 23, 2026.
Company states the resignation was for personal reasons, not a disagreement with the company.
The filing was signed by CFO John Darwin on September 28, 2026.
Chesapeake Utilities designated Jeffrey S. Sylvester, its Senior Vice President and Chief Financial Officer, as principal financial officer, and Michael D. Galtman, its Senior Vice President and Chief Transformation Officer, as principal accounting officer, both on September 28, 2026. The filing states no compensation changes were made in connection with either designation, so the change is administrative in nature for shareholders.
Jeffrey S. Sylvester was designated principal financial officer on September 28, 2026; he was appointed CFO effective July 1, 2026
Michael D. Galtman was designated principal accounting officer on September 28, 2026; he became Chief Transformation Officer effective April 1, 2026
Galtman previously served as Chief Accounting Officer from 2019 to April 2026
No compensation changes were implemented for either officer in connection with the designations
National Healthcare Properties said that on September 25, 2026, the purchaser's termination rights under a July 15, 2026 agreement to sell its 40 outpatient medical facilities for approximately $531 million ended. The company expects the sale to close in the fourth quarter of 2026, subject to customary closing conditions. For shareholders, the filing confirms the pending sale is moving toward closing but does not describe its effect on earnings or future results.
Sale of 40 outpatient medical facilities for approximately $531 million, before transaction expenses, prorations and adjustments
Purchaser's termination rights terminated on September 25, 2026, under the purchase and sale agreement dated July 15, 2026
Closing expected in the fourth quarter of 2026, subject to customary closing conditions
Full agreement to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2026, with some portions possibly omitted
Newbury Street II Acquisition Corp, a special purpose acquisition company, announced an extraordinary general meeting in lieu of an annual general meeting of shareholders, with the date and time to be set in a future definitive proxy statement. The meeting is partly intended to meet Nasdaq's requirement to hold a first annual meeting by December 31, 2026, and the filing says no business beyond the proxy statement items may be transacted.
Shareholder proposals for the meeting must be delivered by October 8, 2026 to the company's Boston address, c/o Thomas Bushey
The meeting is partly to satisfy Nasdaq Listing Rule 5620(a), which requires a first annual meeting on or before December 31, 2026
The company states that the Class I directors' terms will not expire at the meeting because the EGM does not technically constitute an annual general meeting under Cayman Islands law
Clearway Energy subsidiary Swan Purchaser LLC agreed on September 23, 2026 to buy membership interests in Swan TargetCo LLC from an affiliate of Clearway Energy Group for a base price of about $230 million in cash, subject to adjustments. Swan TargetCo will indirectly own Swan Solar, which is developing a 650-megawatt solar facility in Bates County, Missouri, and the deal is expected to close in the third quarter of 2028 subject to conditions.
Base purchase price of approximately $230 million in cash, subject to adjustments tied to a financial model with minimum economic thresholds
Swan Solar is developing and constructing a solar photovoltaic facility with about 650 megawatts of installed capacity in Bates County, Missouri
Closing expected during the third quarter of 2028, subject to customary conditions and third-party actions
Seller is Swan CE Seller LLC, an affiliate of Clearway Energy Group LLC; Purchaser will hold 100% of Target Company class A units at closing
Surf Air Mobility appointed Jason Secore as Chief Financial Officer effective September 30, 2026, succeeding Oliver Reeves, who is stepping down to pursue other opportunities. Reeves will continue to support the company as an advisor. The filing also includes Secore's employment agreement, dated September 24, 2026.
Jason Secore becomes CFO effective September 30, 2026, succeeding Oliver Reeves.
Secore has 18 years of finance leadership experience, most recently as CFO of Matternet.
Oliver Reeves is stepping down to pursue other opportunities and will continue as an advisor.
Employment agreement dated September 24, 2026, effective September 30, 2026, is filed as Exhibit 10.1.
Viking Therapeutics sold 7,857,143 shares of common stock at $35.00 per share and separately sold $225.0 million of 2.00% convertible senior notes due 2032, with underwriters exercising their options in full. Net proceeds were about $297.0 million from the stock sale and about $250.8 million from the notes, which the company intends to use for its VK2735 and VK3019 programs and general corporate purposes. The stock sale adds shares outstanding for existing shareholders, and the notes add debt that could convert into common stock at about $50.75 per share.
Stock: 7,857,143 shares at $35.00 per share, plus 1,178,571 option shares exercised in full on September 24, 2026; closed September 25, 2026; net proceeds about $297.0 million
Notes: $225.0 million of 2.00% convertible senior notes due October 15, 2032, plus a $33,750,000 option exercised in full on September 24, 2026; net proceeds about $250.8 million
Conversion price about $50.75 per share (19.7044 shares per $1,000 principal); company may settle conversions in cash, shares or a combination
Proceeds intended for VK2735 and VK3019 clinical programs and general corporate purposes
Sabre Financial Borrower, a Sabre subsidiary, issued $1.35 billion of 9.875% senior secured notes maturing October 15, 2032, and used the proceeds to refinance part of Sabre GLBL's debt and repurchase portions of its 10.750% and 11.125% notes due 2029 through tender offers. The filing also reports early tender results showing more than 90% of a separate 11.125% note series tendered, which the company plans to redeem, so the refinancing reshapes Sabre's debt structure and secured creditor position.
SPV Notes: $1.35 billion principal, 9.875% annual interest, payable April 15 and October 15, maturing October 15, 2032
Sabre GLBL accepted about $251.9 million of 10.750% 2029 notes at $992.50 per $1,000 principal, with proration of about 84.0%
Early tender results: $930.7 million, or 93.07%, of the 11.125% 2029 notes tendered by September 25, 2026; redemption expected October 13, 2026
Settlement of the tender offers is expected September 28, 2026
AST SpaceMobile's Compensation Committee adopted a Senior Management Change of Control Severance Policy on September 25, 2026, covering the CEO, President, and all Executive and Senior Vice Presidents. The policy sets cash severance, benefit continuation, and equity vesting terms that apply if an executive is terminated without cause or resigns for constructive discharge around a change of control.
Adopted September 25, 2026; applies to the CEO, the President, and all EVPs and SVPs, including all named executive officers
CEO payment multiple is 2.0 times base salary plus target bonus; other eligible employees receive 1.5 times
Benefit continuation runs 24 months for the CEO and 18 months for other eligible employees; performance awards convert to time-based awards on a change of control
Nexalin Technology received a Nasdaq Hearings Panel decision allowing its common stock to stay listed on The Nasdaq Capital Market, subject to conditions. The company must meet the $1.00 minimum bid price by September 28, 2026 and the $2,500,000 stockholders' equity requirement by January 4, 2027, or its stock faces delisting.
Panel granted continued listing in a notice received September 25, 2026.
Company must show a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions.
Stockholders' equity must meet the $2,500,000 minimum by January 4, 2027.
Filing states there can be no assurance the company will meet the conditions.
Exascale Labs reported fiscal 2026 revenue of $14.8 million, up 111% from $7.0 million, but its net loss widened to $12.2 million from $7.7 million. The loss increase reflects higher operating expenses and a $7.4 million non-cash fair value change on simple agreements for future equity (SAFEs), which converted into Class A common stock when the Nasdaq business combination closed on August 27, 2026, eliminating a $29.1 million liability.
Revenue was $14.8 million versus $7.0 million; revenue from the intelligent computing power service rose 124.0%.
Net loss was $12.2 million versus $7.7 million, including a $7.4 million change in fair value of SAFEs.
Operating expenses rose to $7.2 million from $4.2 million; gross margin was 16.3% versus 15.8%.
Business combination closed August 27, 2026, with approximately $11.8 million in net cash proceeds; shares began trading on Nasdaq as XLAB on August 28, 2026.
U.S. Physical Therapy entered a 45-month forward-starting interest rate swap with Bank of America on September 22, 2026, with an initial notional amount of $170.6 million. The swap fixes the variable interest rate on the term debt under its April 14, 2026 credit agreement, starting June 30, 2027, when its existing swap expires. The filing describes this as a hedge on borrowing costs, with no earnings figures disclosed.
Swap notional amount: $170.6 million, reflecting term loan amortization as of the effective date
Company pays a fixed rate of 4.578% per annum and receives one-month SOFR; swap effective June 30, 2027
Swap terminates April 14, 2031; Bank of America is counterparty and Administrative Agent under the credit agreement
The Trustee issued a release answering Unit Holder questions about administrative expenses, a 2017–2020 joint interest audit adjustment, Hilcorp capital spending, and liquidity. It states general and administrative expenses fell by about $976,000 year over year, mainly due to costs from the 2024 trustee transition that did not recur, and that the $2,000,000 Texas Bank credit facility, maturing May 21, 2027, is being discussed for extension, renewal, or replacement.
General and administrative expenses decreased by approximately $976,000 year over year, mainly from non-recurring 2024 trustee transition costs
Outstanding principal on the $2,000,000 Texas Bank Line of Credit was approximately $1,075,400 as of September 18, 2026; the facility matures May 21, 2027
The Trustee is in talks with Texas Bank and evaluating other financing sources, including other commercial lenders, Unit Holders, and private lenders
National newswire distribution of monthly press releases will be restored, beginning with the October 2026 release
Inhibrx Biosciences posted an updated corporate presentation to its website on September 28, 2026, and filed it as Exhibit 99.1 to this 8-K. The presentation shows early Phase 2 HexAgon-HN data for INBRX-106 combined with pembrolizumab, and it says a planned 50-patient expansion of the HPV-positive cohort may support a potential accelerated approval path by the end of 2028 or early 2029. The filing reports no new financial results, and the company states it has no obligation to update the materials.
HPV-positive cohort: confirmed objective response rate of 80.0% (8 of 10) with INBRX-106 plus pembrolizumab, versus 33.3% (3 of 9) with pembrolizumab alone, per the presentation.
Overall randomized population: objective response rate of 48.3% versus 26.5%, with a primary endpoint of cORR per the presentation; data cutoff August 19, 2026.
The company says it had $219.5 million in cash and cash equivalents and 14.7 million common shares outstanding as of August 6, 2026.
The presentation says the study amendment adds 50 HPV-positive patients, with potential accelerated approval by end of 2028 or early 2029.
AAR CORP. reported first-quarter fiscal 2027 results for the period ended August 31, 2026, with sales up 24% to $918.0 million and GAAP diluted EPS of $1.00, compared with $0.95 a year earlier. The company also announced a definitive agreement to acquire a 65% controlling interest in MRO Holdings, and the guidance it gave excludes that acquisition's effect, so shareholders face both the quarterly gains and a large pending deal.
Q1 sales of $918.0 million, up 24% from $739.6 million; GAAP net income of $40.1 million versus $34.4 million
Adjusted diluted EPS of $1.49, up from $1.08; adjusted EBITDA of $116.5 million, up 34%
Full-year fiscal 2027 sales growth guidance (ex. LCP) changed to low teens from low double-digits to low teens; second-quarter sales growth guidance set at 14% to 16%
Net debt of $780.5 million and net leverage of 1.81x at August 31, 2026; acquisition expenses rose to $19.6 million from $4.4 million
PCB Bancorp, the holding company for PCB Bank, said its Board approved on September 23, 2026 a share repurchase program for up to 700,000 shares of common stock, authorized through September 22, 2027. The filing says the company may buy shares in the open market, in block purchases, or in privately negotiated deals, and that it intends to use a Rule 10b5-1 trading plan administered by an independent broker.
Board approved the program on September 23, 2026, for up to 700,000 shares of common stock
Program is authorized through September 22, 2027 and may be modified, discontinued, or suspended at any time
Company is not obligated to buy any specific number of shares; timing and price are at its discretion
Company intends to use a Rule 10b5-1 trading plan administered by an independent broker, subject to price, volume and timing restrictions
Viking Acquisition Corp. I, a special purpose acquisition company, said it expects to complete its business combination with NorthStar Earth & Space Inc. on September 30, 2026. The combined company is expected to begin trading as NorthStar Earth & Space Enterprises, Inc. on NYSE American on October 1, 2026, which matters to shareholders because it changes the company's listing venue and ticker.
Expected closing of the business combination: Wednesday, September 30, 2026, subject to customary closing conditions
Expected first day of trading on NYSE American: Thursday, October 1, 2026, under NSTR for common shares and NSTR.WS for public warrants
Viking will transfer its listing from the New York Stock Exchange to NYSE American in connection with the closing
StandardAero announced that Chief Operating Officer Kimberly Ernzen will no longer serve in that role as of September 28, 2026. She will stay employed through December 31, 2026 to support the leadership transition, and the company expects to enter into a transition agreement with her, terms not yet determined.
Kimberly Ernzen ceases to be Chief Operating Officer effective September 28, 2026
Ernzen remains employed and supports the leadership transition through December 31, 2026
Transition agreement terms have not yet been determined by the company
At an Analyst Day on September 28, 2026, CAMP4 Therapeutics described the design and timing of its planned Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder and gave a pipeline update. The company expects to dose the first patient by the end of 2026 and targets topline data in the first half of 2028, so the update sets out timelines but reports no clinical results or financial figures.
The company expects to dose the first patient in the ASCEND trial by the end of 2026 and targets topline data in the first half of 2028.
The trial plans three multiple ascending dose cohorts with a minimum of eight participants each, randomized 3:1 to intrathecal CMP-002 or a sham procedure.
The company expects to designate a development candidate in its SHANK3 program for Phelan-McDermid Syndrome in 2027, citing more than 45,000 US patients.
Greenland Mines Ltd. agreed on September 28, 2026 to sell 1,320,000 shares of common stock in a direct registered offering to institutional investors, with expected net proceeds of about $17.2 million. The offering is expected to close on or about September 29, 2026, and the company plans to use the proceeds with existing cash for its Greenland mining operations and general working capital, which would add new shares outstanding and dilute existing holders.
1,320,000 shares of common stock offered; expected net proceeds of about $17.2 million after offering expenses
Expected closing on or about September 29, 2026, subject to customary closing conditions
On September 23, 2026, the company terminated its August 24, 2026 at-the-market sales agreement with A.G.P./Alliance Global Partners, under which $1,388,827.04 of shares had been sold
IDT reported fiscal fourth-quarter 2026 revenue of $339.0 million, up 7%, and income from operations of $33.2 million, up 52%. For the full fiscal year, revenue rose 5% to $1,298.0 million and GAAP diluted EPS increased to $3.46 from $3.01. The company guided fiscal 2027 Adjusted EBITDA to $176 million to $180 million, while full-year operating cash flow fell to $91.1 million from $127.1 million.
Q4 2026 revenue rose 7% to $339.0 million; income from operations rose 52% to $33.2 million
FY 2026 revenue rose 5% to $1,298.0 million; income from operations rose 21% to $121.2 million
FY 2026 GAAP diluted EPS was $3.46, up from $3.01 in FY 2025
FY 2027 outlook: Adjusted EBITDA of $176 million to $180 million; FY 2026 net cash from operations fell to $91.1 million from $127.1 million
Unicycive Therapeutics disclosed that a securities class action was filed on September 3, 2026, in the U.S. District Court for the Northern District of California against the company and certain officers. The suit alleges violations of federal securities laws tied to public statements about the company's new drug application for oxylanthanum carbonate phosphate binder. The company says the claims are meritless and plans to defend the lawsuit vigorously, but the filing does not state any financial impact.
Class action filed September 3, 2026, in U.S. District Court for the Northern District of California
Suit names the company and certain officers and alleges federal securities law violations
Allegations relate to public statements about the new drug application for oxylanthanum carbonate phosphate binder for hyperphosphatemia in dialysis patients with chronic kidney disease
Company says the claims are meritless and intends to vigorously defend
Gain Therapeutics said its senior vice president of finance and principal financial officer, Gianluca Fuggetta, will resign effective September 30, 2026, to pursue other opportunities. The board appointed CEO Gene Mack as interim chief financial officer effective October 1, 2026, and the company is searching for a permanent replacement.
Gianluca Fuggetta gave notice on September 22, 2026; resignation effective September 30, 2026
Gene Mack, current President and CEO, appointed interim CFO effective October 1, 2026
Mack also assumes principal financial and principal accounting officer duties; his employment terms are unchanged
Company is conducting an ongoing search for a permanent principal financial officer
Wintergreen Acquisition Corp. issued a $184,635 non-interest-bearing promissory note to its sponsor, MACRO DREAM Holdings Limited, to fund a deposit into its trust account for an extension. The board approved extending the deadline for completing its business combination with KIKA Technology Inc. from September 30, 2026 to October 30, 2026, and the company says it continues to pursue that deal.
Note principal of $184,635 issued September 28, 2026 to sponsor MACRO DREAM Holdings Limited
Business combination deadline extended from September 30, 2026 to October 30, 2026
Sponsor may convert unpaid note principal into units at $10.00 per unit upon a business combination
Note is forgiven and the sponsor waives trust account claims if no business combination is completed
Graphic Packaging Holding Company appointed Aditya Gandhi as Vice President and Chief Accounting Officer effective September 28, 2026, reporting to Interim Chief Financial Officer Charles D. Lischer. Gandhi previously served as Chief Accounting Officer at AptarGroup and Sonoco Products Company, and the filing discloses his pay package, which includes restricted stock units and a cash sign-on bonus.
Gandhi, age 46, joins as Vice President and Chief Accounting Officer, reporting to Interim CFO Charles D. Lischer
One-time restricted stock unit grant valued at approximately $715,000, vesting ratably over three years
Cash sign-on bonus of $105,000
Prior roles include Chief Accounting Officer at AptarGroup (from June 2026) and Sonoco Products Company (August 2022 to May 2026)
Precision Optics reported fiscal 2026 revenue of $31.5 million, up about 65%, and a narrower net loss of $3.6 million, or $0.43 per share, compared with $5.8 million, or $0.85 per share, a year earlier. The company guided fiscal 2027 revenue to $30 million to $33 million, similar to fiscal 2026, citing a pause in orders from an existing satellite customer that it expects to partly offset with other programs and a stronger second half. For shareholders, the results show strong growth and smaller losses, but the outlook projects no revenue growth for the coming year.
Fourth quarter ended June 30, 2026: revenue of $8.8 million, up about 42% from $6.2 million a year earlier, with a net loss of $0.1 million versus $1.4 million.
Fiscal 2026 revenue of $31.5 million, up about 65% from $19.1 million; net loss of $3.6 million, or $0.43 per share, versus $5.8 million, or $0.85 per share.
Fiscal 2027 revenue guidance of $30 million to $33 million, similar to fiscal 2026, reflecting a pause in orders from an existing satellite customer.
Fiscal 2027 Adjusted EBITDA guidance of $(1.2) million to $(1.7) million loss, compared with a $(2.1) million loss in fiscal 2026.
Teledyne said Vice Chairman Jason VanWees will retire effective February 1, 2027. Mary Grace DeForest, Senior Vice President and General Manager of Teledyne Microwave, will become Corporate Vice President of Investor Relations and Mergers and Acquisitions effective November 1, 2026. VanWees has led the identification and acquisition of 75 businesses for cumulative consideration of $12.8 billion, so the change affects the company's acquisition and investor communication roles.
Jason VanWees, Vice Chairman, retires effective February 1, 2027, at age 55
Mary Grace DeForest appointed Corporate Vice President of Investor Relations and M&A, effective November 1, 2026
DeForest is SVP and General Manager of Teledyne Microwave, with 880 employees and annual revenue of $320 million
VanWees led acquisitions of 75 businesses for cumulative consideration of $12.8 billion
PetMed Express increased the share reserve under its 2024 Inducement Incentive Plan by 500,000 shares, bringing the total to 850,000, effective September 27, 2026. The increase covers equity grants promised to Jeffrey Allen Willard, the new Chief Executive Officer, whose start date is September 28, 2026, so the change adds potential dilution for shareholders.
Share reserve under the Inducement Incentive Plan rises by 500,000 shares to 850,000 total.
The increase matches 250,000 restricted stock shares plus 250,000 performance share units promised to CEO Jeffrey Allen Willard.
Willard's start date is September 28, 2026; the plan was amended and restated as of September 27, 2026.
No other changes were made to the original plan, per the filing.
Ready Capital Corporation said its subsidiary ReadyCap Holdings II closed a private placement of $225.0 million of 10.00% senior secured notes due 2031 on September 28, 2026. On the same day, an indirect subsidiary redeemed the entire $350.0 million of its 4.50% senior secured notes due 2026 at 100% of principal plus accrued interest. The filing is a financing refinancing update and does not report revenue, earnings or guidance.
New Notes: $225.0 million aggregate principal, 10.00% coupon, due 2031, closed September 28, 2026
Existing Notes: entire $350.0 million 4.50% senior secured notes due 2026 redeemed September 28, 2026
Redemption price: 100% of principal amount plus accrued and unpaid interest
Offering was previously priced and disclosed in a Form 8-K filed September 18, 2026
Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. The filing says Dr. Roberts will receive a base salary of $825,000, a target bonus of 60% of base pay, and about $1.25 million in target equity grants, and that Dr. Keswani will receive severance under the company's Executive Severance Plan.
Dr. Keswani's service as Chief Medical Officer ended September 25, 2026, by mutual agreement with the Board.
Dr. Roberts was appointed Chief Medical Officer effective September 28, 2026, with an annual base salary of $825,000 and a target bonus of 60% of base pay for 2026.
Target equity grants total about $1.25 million: stock options of about $625,000, restricted stock units of about $250,000, and performance-vesting restricted stock units of about $375,000.
The final Employment Agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Jefferies reported results for the quarter ended August 31, 2026, with net earnings attributable to common shareholders of $261 million, up from $224 million a year earlier, and total net revenues of $2.22 billion, up from $2.05 billion. Investment Banking and Equities reached record quarterly revenue, while Fixed Income and Asset Management declined. The board also raised the share buyback authorization to $250 million and declared a $0.40 quarterly dividend.
Total net revenues of $2.22 billion versus $2.05 billion in the prior year quarter.
Diluted earnings per voting common share of $1.08 versus $1.01; return on adjusted tangible shareholders' equity of 13.5% versus 13.6%.
Asset management fees and investment return of $34 million versus $84 million in the prior year quarter.
Quarterly dividend of $0.40 payable November 25, 2026; buyback authorization increased to $250 million.
Pathfinder Bancorp, Inc. declared a quarterly cash dividend of $0.10 per voting and non-voting common share, related to the fiscal quarter ending September 30, 2026. Shareholders of record on October 16, 2026 will receive the payment on November 6, 2026.
Dividend amount: $0.10 per share on voting and non-voting common stock
Record date: October 16, 2026
Payment date: November 6, 2026
Dividend relates to the third quarter 2026 fiscal quarter
Asana's board appointed CEO Dan Rogers as Board Chair effective September 25, 2026, succeeding Dustin Moskovitz, who remains a director. The board also expanded from seven to nine members with Tom Berquist and Jerry Ting, and named Heather Le as Chief Accounting Officer and Principal Accounting Officer. The filing describes these as governance and leadership changes and does not report any financial results.
Dan Rogers, CEO and a Class III director, was appointed Board Chair effective September 25, 2026, and is not eligible for director compensation as an employee.
Tom Berquist (Class II, term to the 2028 annual meeting) and Jerry Ting (Class I, term to the 2027 annual meeting) were appointed directors, increasing the board from seven to nine members.
Heather Le was appointed Chief Accounting Officer with a $400,000 annual base salary, a 15% initial target bonus and a $1,000,000 target-value RSU grant subject to Compensation Committee approval.
Hain Celestial's common stock was transferred from The Nasdaq Global Select Market to The Nasdaq Capital Market on September 24, 2026, and Nasdaq granted an additional 180-day period, to March 22, 2027, to regain the $1.00 minimum bid price. The company may need a reverse stock split, and it states there is no assurance it will regain or maintain compliance. Separately, Chief Accounting Officer Michael J. Ragusa plans to resign effective November 1, 2026, and CFO Lee A. Boyce will also take on the principal accounting officer role.
Stock transferred to The Nasdaq Capital Market at the opening of business on September 24, 2026, and continues to trade as HAIN
Nasdaq deficiency: closing bid price below $1.00 for 30 consecutive business days; second compliance period ends March 22, 2027
Compliance requires closing at or above $1.00 for at least ten consecutive business days; a reverse stock split may be used if necessary
Michael J. Ragusa resigns as SVP, Chief Accounting Officer, effective November 1, 2026; Lee A. Boyce takes on the principal accounting officer role
Workhorse Group's board adopted a Value Creation Incentive Plan on September 22, 2026, and granted performance awards to CEO Scott Griffith ($15 million target) and CFO Jody Davis ($6.5 million target). Payouts depend on revenue, gross margin, operating cash flow and market capitalization milestones over a performance period from October 1, 2026 to September 30, 2031.
CEO Scott Griffith target award is $15 million; CFO Jody Davis target award is $6.5 million.
Performance period runs from October 1, 2026 to September 30, 2031.
Equity value milestone (40% of target) requires a $500 million average market capitalization over any 45-trading-day period.
Awards may be paid in cash or, at the Committee's election, in common stock.
OPENLANE's subsidiaries amended two receivables purchase facilities on September 25, 2026, extending the termination date of each from January 31, 2028 to January 31, 2030. The filing describes the extension as a term extension and does not mention new borrowing capacity, pricing changes, or costs.
U.S. facility: Second Amendment to the Tenth Amended and Restated Receivables Purchase Agreement, signed September 25, 2026, extends termination date to January 31, 2030
Canadian facility: Amendment No. 4 to the Receivables Purchase Agreement dated March 1, 2023, signed September 25, 2026, extends termination date to January 31, 2030
Full amendment texts will be filed as exhibits to the Form 10-Q for the quarter ended September 30, 2026
Voyager Technologies issued $402.5 million of 0% convertible senior notes due October 15, 2032, on September 28, 2026, including $52.5 million from the initial purchasers' full option exercise. The company reported net proceeds of approximately $391.6 million and plans to use about $52.5 million to fund capped call transactions, with the rest for general corporate purposes. Holders can convert into cash, Class A common stock, or a mix, which could dilute existing shareholders if the notes are converted into shares.
Principal: $402.5 million, including $52.5 million from the full exercise of the initial purchasers' option
Initial conversion price of approximately $40.82 per share, a premium of about 30% over the $31.40 close on September 23, 2026
Capped calls have a cap price of $78.50 per share and cost approximately $52.5 million
Net proceeds of approximately $391.6 million; the notes mature October 15, 2032
Vail Resorts reported fiscal 2026 results for the year ended July 31, 2026, with net income attributable to the company falling to $147.5 million from $280.0 million, which it attributed mainly to weather. The company also gave fiscal 2027 guidance of $158 million to $233 million in net income and $805 million to $865 million in Resort Reported EBITDA, and said season pass unit sales were down about 12% through September 18, 2026.
Fiscal 2026 net income attributable to Vail Resorts was $147.5 million, versus $280.0 million a year earlier; Resort Reported EBITDA was $745.7 million, versus $844.1 million.
Fourth-quarter net loss attributable to Vail Resorts was $190.2 million, compared with a $182.4 million loss in the prior-year quarter.
Fiscal 2027 guidance: net income attributable to Vail Resorts of $158 million to $233 million and Resort Reported EBITDA of $805 million to $865 million.
Pass product units sold through September 18, 2026 fell about 12%, and sales dollars fell about 6%; the quarterly dividend is $2.22 per share, payable October 27, 2026.
Emmis Acquisition Corp. appointed Kenneth C. Greenberg as a Class II director on September 25, 2026, and named him chairman of the Compensation Committee, with additional seats on the Audit and Nominating and Corporate Governance Committees. Seth Farbman was removed from all three of those committees but remains a Class I director. The filing describes board committee changes and a standard indemnification agreement, with no financial results or guidance included.
Kenneth C. Greenberg appointed Class II director on September 25, 2026; he is age 70 and the filing says he qualifies as independent under Nasdaq and Rule 10A-3 standards.
Greenberg chairs the Compensation Committee and also sits on the Audit and Nominating and Corporate Governance Committees.
Seth Farbman removed from the Audit, Compensation, and Nominating and Corporate Governance Committees on September 25, 2026; he continues as a Class I director.
Emmis Capital Sponsor LLC transferred 11,667 Class B ordinary shares to Greenberg in connection with his appointment.
MediciNova amended its office lease, extending the end date from January 31, 2027 to April 30, 2030, and agreed to rent increases starting February 1, 2027. The filing is an administrative lease change with no revenue, earnings, or guidance effect, though it commits the company to a longer occupancy period at higher rent.
Lease end date extended from January 31, 2027 to April 30, 2030, unless terminated earlier under the lease terms
Rent increases take effect February 1, 2027; the filing does not state amounts
Amendment dated September 23, 2026, with Newport Gateway Office LLC; original lease dated July 20, 2021 with Irvine Company LLC
Full amendment expected to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026
Adeia Inc. said Dipti Vachani, a former Arm Limited executive, will become chief executive officer and a board member effective October 12, 2026, succeeding Paul E. Davis, who is leaving to focus on his health and personal pursuits. The filing sets out her pay package, including a $730,000 base salary and an $11,000,000 target equity grant, along with severance terms and a consulting arrangement for Davis.
Vachani's CEO start date and board seat are both effective October 12, 2026; Davis's consulting agreement runs through December 31, 2026.
Vachani's offer letter provides a $730,000 base salary and a target bonus of 100% of base salary.
Target equity grants total $11,000,000, including a $4,400,000 time-based RSU award and a $6,600,000 performance-based RSU award.
Davis will receive a fixed consulting fee of $183,000.
Humacyte appointed two new directors, Scott Coward and Paul Kuznik, effective September 22, 2026, and announced the appointments in a September 28, 2026 press release. Mr. Coward joins the Audit Committee and Mr. Kuznik joins the Commercial Committee, and both will receive standard non-employee director compensation. The filing reports no financial results and no change in management roles, so the change has limited direct impact on shareholders.
Scott Coward appointed Class I director with a term expiring in 2028; former Exact Sciences executive and board member
Paul Kuznik appointed Class II director with a term expiring in 2029; former CEO of Bolton Medical
Each director receives a $50,000 annual cash retainer, $5,000 per year for committee service, and an option to purchase 125,000 shares of common stock
On September 16, 2026, IQSTEL amended its 2025 agreement to acquire 51% of GlobeTopper, LLC, replacing a $500,000 payment originally due in restricted common stock with $500,000 in cash. The company must pay $80,000 within five business days, then $70,000 on the first business day of each of six following months, and the payments are secured by its GlobeTopper interest. If the company fails to cure a missed payment, the seller could seek to rescind the deal and take back the 51% interest, which would end the related earn-out obligations.
September 16, 2026: amendment replaces $500,000 in buyer shares with a $500,000 cash payment; the company has no further obligation to issue those shares
Payment schedule: $80,000 within five business days, then $70,000 on the first business day of each of six consecutive months
Missed payments not cured within 30 days after notice are an Event of Default; the seller may accelerate, foreclose on the collateral, or rescind and reclaim the 51% GlobeTopper interest
At its 2026 Annual Meeting on September 28, 2026, Phio Pharmaceuticals stockholders approved an amendment that raises the shares available under its 2020 Long Term Incentive Plan by 1,500,000 to a total of 2,452,017. Stockholders also re-elected six directors and ratified Grant Thornton, LLP as the independent auditor for 2026. The larger share pool allows more shares to be issued under the plan than before.
Plan Amendment approved; shares available under the 2020 Plan rise by 1,500,000 to 2,452,017.
Plan proposal vote: 1,155,945 for, 194,070 against, 34,468 abstained, and 3,823,097 broker non-votes.
All six director nominees elected, including Robert J. Bitterman, to serve until the 2027 Annual Meeting; Grant Thornton ratified with 5,087,608 votes for.
5,207,580 shares were present of 11,617,250 outstanding at the August 4, 2026 record date.
Gossamer Bio received a Nasdaq letter on September 25, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had completed a 1-for-80 reverse stock split on September 10, 2026, with split-adjusted trading beginning September 11, 2026. The filing shows the listing issue is resolved, but it does not report any change to financial results.
Nasdaq letter dated September 25, 2026 confirms compliance with the minimum bid price rule under Nasdaq Listing Rule 5450(a)(1)
The matter followed a Nasdaq letter received April 8, 2026, after the stock failed to trade at $1.00 or more for 30 consecutive business days
1-for-80 reverse stock split effective September 10, 2026; split-adjusted trading began September 11, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.